Fubei Biotech Closes Over 100 Million Yuan Pre-B Round to Accelerate Development of Novel Neurological Drugs
Its products are all either global category leaders or world-class.
On December 12, 4B Technologies Investments Ltd. announced the completion of a Pre-B funding round exceeding RMB 100 million. The round was led by Fortune Venture Capital, with participation from Bloomage Lanya, Fang Sheng Capital, Zhongguancun Collaborative Innovation Fund, and Dao Capital. Existing investors Gaorong Ventures and Tsingyuan Capital also continued their support. The proceeds will be used to advance clinical programs and expand preclinical R&D pipelines. Gaorong Ventures had led 4B Technologies' Series A+ round in 2019 and has participated in subsequent funding rounds.
4B Technologies is a biotechnology company focused on developing novel therapeutics for central nervous system (CNS) diseases. It was founded by renowned neuroscientist and Tsinghua University professor Bai Lu, PhD, and former GSK R&D Vice President Xiaoming Guan, PhD. The company employs a distinctive R&D strategy, maintains industry-leading proprietary intellectual property, and has built a diversified product portfolio with broad market potential and balanced short- and long-term opportunities, supported by multiple technology platforms that enable neuroscience innovation. The company has established early discovery, preclinical, and clinical research centers in Suzhou and Beijing.
Accelerating Novel R&D Programs Toward Clinical Development
4B Technologies focuses on neurotrophic factor signaling pathways and neuroinflammatory mechanisms, dedicated to developing innovative drugs for treating neurological diseases with substantial unmet medical needs and significant national health impact. To date, 4B Technologies' pipeline comprises nine innovative programs spanning small-molecule chemical drugs and large-molecule biologics, with target products positioned as either global first-in-class or world-leading. Programs that have entered or are about to enter clinical trials include: FB-1071 for amyotrophic lateral sclerosis (ALS); FB1001 for acute optic nerve injury; and the FB1006 ALS study led by Peking University Third Hospital with 4B Technologies as a major participant. Additionally, FB1003 and FB1008—novel mechanism candidates for chronic pain and Alzheimer's disease—have advanced to the preclinical stage.
Throughout its R&D process, 4B Technologies has built blood-brain barrier delivery technology platforms, animal disease model platforms, and biomarker discovery platforms, substantially enhancing the innovation and translatability of its drug candidates while accelerating pipeline development.
Addressing the CNS Drug Development Challenge, Meeting Medical and Market Demands
"New tools in neuroscience research and rapidly advancing interdisciplinary technologies have generated considerable investment interest in the field, driving substantial progress in CNS drug development and novel therapeutic modalities. More and more challenges are being overcome, and the sector is approaching a golden age of development," said Xiaoming Guan, PhD, President of 4B Technologies. "Yet the rapid translation from basic research to clinical application still faces numerous hurdles. 4B Technologies is committed to addressing the challenges in CNS drug development through a comprehensive, systematic R&D strategy and technical solutions. We are deeply grateful for the strong trust and tremendous support from our outstanding biopharma investment partners. 4B will redouble its efforts, leveraging our robust capabilities to tackle these challenges head-on, improving the success rate of novel drug development, contributing to alleviating patient suffering, and accelerating the realization of substantial returns on investment."
"We are honored to have earned the recognition and support of so many leading investors in the biotech and healthcare space," said Jing Su, PhD, CEO of 4B Technologies. "While CNS drug development faces multiple challenges, breakthroughs in life sciences technology, widespread application of artificial intelligence, and translational research based on large cohorts and real-world data are making neurological diseases an increasingly important area of industry investment. 4B Technologies focuses on modulating pathophysiological processes—enhancing neuroprotection and repair while suppressing neuroinflammation—to slow or halt disease progression, addressing enormous medical and market needs. With this funding round, we will accelerate our existing clinical-stage programs while advancing more novel R&D projects into clinical development."
